OSE Immunotherapeutics announced a new organization within its Board of Directors with the appointment of Dominique Costantini as Chairman of the Board and the appointment of Alexis Peyroles as Chief Executive Officer. These changes, effective immediately, are based on the recommendation of the Nomination and Remuneration Committee with the aim of positioning the company for growth given the recent developments. Dominique Costantini, company's co-founder and former Chief Executive Officer, is appointed as Chairman of the Board of Directors, and also will serve as Director of Early Development.

Alexis Peyroles, former Chief Operating Officer, Operations, is appointed as Chief Executive Officer. Dominique Costantini succeeds Gérard Tardy who will not run for a mandate of Board member at the next shareholders' general meeting. The management team around Alexis Peyroles has recently been strengthened with the additions of Bérangère Vasseur, MD, Chief Medical Officer Immuno-Oncology (broad experience in oncology development while at Roche and at several biotechnology companies) and Emilienne Soma, PharmD, Ph.D., Director of Pharmaceutical Program Development (experience in R&D management and in alliances in several biotechnology companies) who have recently joined the company.

The team also includes Bernard Vanhove Ph.D., Chief Operating Officer and Director of R&D and International Scientific Collaborations; Nicolas Poirier, Ph.D., Chief Scientific Officer; Frédérique Corallo, MD, Chief Medical Officer Immunotherapies and Autoimmune Diseases; Jean-Pascal Conduzorgues, PhamD, Qualified Person; and Anne-Laure Autret-Cornet, Chief Financial Officer. Maryvonne Hiance, Director of Strategy and Dominique Costantini, in her additional role as Director of Early Development, bring their expertise to this team.